Chester County News and Community Website
RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently granted its request for …
Read More RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) this week announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 …
Read More
HORSHAM, PA — The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with …
Read More
RADNOR, PA — NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical stage pharmaceutical company, today announced it has filed an application with U.S. Food and Drug Administration (FDA) requesting Emergency Use …
Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of …
Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or …
Read More
MALVERN, PA — Ocugen, Inc., (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from …
Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration has issued an emergency use authorization (EUA) for casirivimab and imdevimab to be administered together for the treatment of mild to moderate …
Read More
WASHINGTON, D.C. — As part of the U.S. Department of Veterans Affairs (VA) fight against the COVID-19 pandemic, the department announced its nationwide effort to recruit volunteers for COVID-19 clinical …
Read More
DEVON, PA — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) announced that the U.S. Food and Drug Administration has granted orphan drug designation for cannabidiol (CBD) for use in treating 22q11.2 deletion …
Read More